Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

doi:10.1200/JCO.21.02838

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jul 2022

Parsons D Williams, Janeway Katherine A, Patton David R, Winter Cynthia L, Coffey Brent, Williams P Mickey, Roy-Chowdhuri Sinchita, Tsongalis Gregory J, Routbort Mark, Ramirez Nilsa C, Saguilig Lauren, Piao Jin, Alonzo Todd A, Berg Stacey L, Fox Elizabeth, Hawkins Douglas S, Abrams Jeffrey S, Mooney Margaret, Takebe Naoko, Tricoli James V, Seibel Nita L

Abstract excerpt

PURPOSE: The National Cancer Institute-Children's Oncology Group Pediatric MATCH trial aimed to facilitate evaluation of molecular-targeted therapies in biomarker-selected cohorts of childhood and young adult patients with cancer by screening tumors for actionable alterations. PATIENTS AND METHODS: Tumors from patients age 1-21 years with refractory solid tumors, lymphomas, or histiocytic disorders were subjected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Clinical Protocols

Share to Infant

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to United States

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 35353553
DOI: 10.1200/JCO.21.02838
PMCID: PMC9273376

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.PMID 35353553Read ↗

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.Semantic proximity Read ↗

Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry.Semantic proximity Read ↗

Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.Semantic proximity Read ↗

Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.Semantic proximity Read ↗

Integrating genomics into clinical pediatric oncology using the molecular tumor board at the Memorial Sloan Kettering Cancer CenterSemantic proximity Read ↗

An institutional review of genomic sequencing in pediatric solid tumors.Semantic proximity Read ↗

Molecular Profiling of Hard-to-Treat Childhood and Adolescent CancersSemantic proximity Read ↗

Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterationsSemantic proximity Read ↗

Molecular Profiling in Pediatric Cancer Identifies Potential Targeted Therapies.Semantic proximity Read ↗

Functional Precision Medicine Enhances Clinical Outcomes of Relapsed/Refractory Pediatric and Adolescent Cancer PatientsSemantic proximity Read ↗

Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.Semantic proximity Read ↗

Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.